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Abstract 1 
Background 2 
Unsupervised learning methods such as Hierarchical Cluster Analysis are commonly used 3 
for the analysis of genomic platform data. Unfortunately, such approaches ignore the well 4 
documented heterogeneous composition of prostate cancer samples. Our aim is to use more 5 
sophisticated analytical approaches to deconvolute the structure of prostate cancer 6 
transciptome data providing novel clinically actionable information for this disease.  7 
Methods 8 
We apply an unsupervised model called Latent Process Decomposition (LPD), which can 9 
handle heterogeneity within individual cancer samples, to genome-wide expression data 10 
from eight prostate cancer clinical series including 1,785 malignant samples with the clinical 11 
endpoints of PSA failure and metastasis.   12 
Results 13 
We show that PSA failure is correlated with the level of an expression signature called 14 
DESNT (HR = 1.52, 95% CI = [1.36, 1.7], P = 9.0x10-14, Cox model) and that patients with a 15 
majority DESNT signature have an increased metastatic risk (X2-test, P = 0.0017, and 16 
P = 0.0019).  Additionally, we develop a stratification framework that incorporates DESNT 17 
and identifies three novel molecular subtypes of prostate cancer. 18 
Conclusions 19 
These results highlight the importance of using more complex approaches for the analysis of 20 
genomic data, may assist drug targeting, and have allowed the construction of a nomogram 21 
combining DESNT with other clinical factors for use in clinical management. 22 
 23 
 24 
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 1 
Background 2 
Driven by technological advances and decreased costs, a plethora of genomic datasets now 3 
exist. This is illustrated by the availability of expression data from over 1.3 million samples 4 
from the Gene Expression Omnibus [1] and DNA sequence data on 25,000 cases from the 5 
International Cancer Genome Consortium [2]. Such datasets have been used as the raw 6 
material for the discovery of disease sub-classes using a variety of mathematical approaches. 7 
Hierarchical clustering, k-means clustering, and self-organising maps have been applied to 8 
expression datasets leading, for example, to the discovery of five molecular breast cancer 9 
types (Basal, Luminal A, Luminal B, ERBB2-overexpressing, and Normal-like) [3]. The 10 
inherent shortcoming of this type of approach is the implicit assumption of sample 11 
assignment to a particular cluster or group. Such analyses are in complete contrast to the 12 
well documented heterogeneous composition of most individual cancer samples [4,5]. 13 
 14 
Unsupervised analysis of prostate cancer transcriptome profiles using the above approaches 15 
have failed to identify robust disease categories that have distinct clinical outcomes [6,7]. 16 
Noting that prostate cancer samples derived from genome wide studies frequently harbour 17 
multiple cancer lineages, and can have intra-tumour variations in genetic compositions [8–18 
10], we applied an unsupervised learning method called Latent Process Decomposition 19 
(LPD) [11] that can take into account the issue of heterogeneity of composition within 20 
individual cancer samples. By heterogeneity we mean that an individual cancer sample can 21 
be made up of several different components that each has distinct properties  We had 22 
previously used Latent Process Decomposition: (i) to confirm the presence of the basal and 23 
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ERBB2 overexpressing subtypes in breast cancer transcriptome datasets [12]; (ii) to 1 
demonstrate that data from the MammaPrint breast cancer recurrence assay would be 2 
optimally analyzed using four separate prognostic categories [12]; and (iii) to show that 3 
patients with advanced prostate cancer can be stratified into two clinically distinct categories 4 
based on expression profiles in blood [13].  LPD (closely related to Latent Dirichlet 5 
Allocation) is a mixed membership model in which the expression profile for a single cancer 6 
is represented as a combination of underlying latent (hidden) signatures. Each latent 7 
signature has a representative gene expression pattern. A given sample can be represented 8 
over a number of these underlying functional states, or just one such state. The appropriate 9 
number of signatures to use is determined using the LPD algorithm by maximising the 10 
probability of the model given the data. 11 
 12 
The application of LPD to prostate cancer transcriptome datasets led to the discovery of an 13 
expression pattern, called DESNT, that was observed in all datasets examined [14]. Cancer 14 
samples were assigned as DESNT when this pattern was more common than any other 15 
signature, and this designation was associated with poor outcomes independently of other 16 
clinical parameters including Gleason, Clinical stage and PSA. In the current paper we test 17 
whether the presence of even a small proportion of the DESNT cancer signature confers 18 
poor outcome and use LPD to develop a new prostate cancer stratification framework. 19 
 20 
Materials and Methods 21 
Transcriptome datasets 22 
Eight publically available transcriptome microarray datasets derived from prostatectomy 23 
samples from men with prostate cancer were used and are referred to as: Memorial Sloan 24 
Kettering Cancer Centre (MSKCC) [7], CancerMap [14], CamCap [6], Stephenson [15], TCGA 25 
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[16], Klein [17], Erho [18], and Karnes [19].  There were 1785 samples from primary 1 
malignant tissue and 173 from normal tissue (Table 1). MSKCC also had data from 19 2 
metastatic cancer samples. The CamCap dataset was produced by combining two Illumina 3 
HumanHT-12 V4.0 expression beadchip datasets (GEO: GSE70768 and GSE70769) obtained 4 
from two prostatectomy series (Cambridge and Stockholm) [6]. The original CamCap [6] 5 
and CancerMap [14] datasets have 40 patients in common and thus 20 of the common 6 
samples were excluded at random from each dataset. Each Affymetrix Exon microarray 7 
dataset was normalised using the RMA algorithm [20] implemented in the Affymetrix 8 
Expression Console software. For CamCap and Stephenson previous normalised values 9 
were used. For the TCGA dataset, the counts per gene previously calculated were used [16] 10 
and transformed using the variance stabilising transformation implemented in the DESeq2 11 
package[21]. For the CamCap and CancerMap datasets the ERG gene alterations had been 12 
scored by fluorescence in situ hybridization [6,14]. Only probes corresponding to genes 13 
measured by all platforms were retained. The ComBat algorithm from the sva R package 14 
and quantile transformation, was used to mitigate series-specific effects. Flow diagrams 15 
presenting each of the analyses performed in the current study, with the datasets used, are 16 
shown in the Supplementary Materials.  The ethical approvals obtained for each dataset are 17 
listed in the original publications.   18 
 19 
Latent Process Decomposition (LPD) 20 
LPD [11,12] is an unsupervised Bayesian approach which breaks down (decomposes) each 21 
sample into component sub-elements (signatures). Each signature is a representative gene 22 
expression pattern. LPD is able to classify complex data based on the relative representation 23 
of these signatures in each sample. LPD can objectively assess the most likely number of 24 
signatures. We assessed the hold-out validation log-likelihood of the data computed at 25 
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various number of signatures and used a combination of both the uniform (equivalent to a 1 
maximum likelihood approach) and non-uniform (missed approach point) priors to choose 2 
the number of signatures. For input, each dataset was reduced to probes that detect the 500 3 
genes with the greatest variance across the MSKCC dataset. For robustness, LPD is run 100 4 
times with different seeds, for each dataset. Out of the 100 runs we selected the run with the 5 
survival log-rank p-value closest to the mode as a representative run that was used for 6 
subsequent analysis. 7 
 8 
OAS-LPD (One Added Sample LPD) 9 
The OAS-LPD algorithm is a modified version of the LPD algorithm in which new sample(s) 10 
are decomposed into LPD signatures, without retraining the model (i.e. without re-11 
estimating the model parameters µgk, σ2gk, and α in Rogers et al. [11]). Only the variational 12 
parameters Qkga and γak, corresponding to the new sample(s), are iteratively updated until 13 
convergence, according to Eq. (6) and Eq. (7) from Rogers et al. 2005 [11]. LPD as presented 14 
by Rogers et al. [11] was first applied to the MSKCC dataset of 131 cancer and 29 normal 15 
samples, as described above. The model parameters µgk, σ2gk, and α, corresponding to the 16 
representative LPD run, were then used to classify additional expression profiles from all 17 
datasets, one sample at a time. A detailed description is provided in the Supplementary 18 
Methods. 19 
 20 
Statistical tests 21 
All statistical tests were performed in R version 3.3.1. For characterisation of signatures, each 22 
sample was assigned to the signature that had the largest gamma (γ) value for that sample. 23 
Correlations 24 
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Pearson correlations between the expression profiles between the MSKCC and CancerMap 1 
were calculated for each of the eight signatures: (i) for each gene we select one 2 
corresponding probe at random; (ii) for each probe we transformed its distribution across all 3 
samples to a standard normal distribution; (iii) the mean expression for each gene across the 4 
samples assigned to signature j (gene subgroup mean) in each dataset was determined; (iv) 5 
the Pearson’s correlation between the gene subgroup mean expression profile in MSKCC vs 6 
the gene subgroup mean expression profile in CancerMap is calculated for each signature. 7 
Differentially expressed and methylated features 8 
Differentially expressed probesets were identified for each signature using a moderated t-9 
test implemented in the limma R package (Benjamin-Hocberg false discovery rate < 0.05, 10 
differentially expressed in at least 50/100 runs; samples assigned to the signature vs the 11 
rest).  12 
Thus differential methylation was assigned at the probe level. Hypo and hypermethylated 13 
genes that are predictive of transcription were identified using the methylMix R package 14 
(functionally differentially methylated in at least 50/100 runs) using genes that are found to 15 
be differentially expressed in that signature as input. Datasets where there were <10 samples 16 
assigned to a signature were removed from the identification of intersection genes for that 17 
signature.  18 
Survival analyses and nomogram 19 
Survival analyses were performed using Cox proportional hazards models, the log-rank test, 20 
and Kaplan-Meier estimator, with biochemical recurrence after prostatectomy as the end 21 
point. For nomogram construction, the Cox proportional hazards model was fitted on the 22 
meta-dataset obtained by combining MSKCC, CancerMap, and Stephenson datasets, and 23 
validated on CamCap, using the rms R package. The Gleason grade was divided into <7, 24 
3+4, 4+3, >7, the pathological stage in T1-T2 vs T3-T4, while DESNT percentage and PSA 25 
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were considered continuous covariates. The missing values for the predictors were imputed 1 
using the flexible additive models with predictive mean matching, implemented in the 2 
Hmisc R package. The linearity of the continuous covariates was assessed using the 3 
Martingale residuals [22]. The lack of collinearity between covariates was determined by 4 
calculating the variance inflation factors (VIF) (VIF values between 1.04 and 3.01) [23]. All 5 
covariates met the Cox proportional hazards assumption, as determined by the Schoenfeld 6 
residuals. The internal validation and calibration of the Cox model were performed by 7 
bootstrapping the training dataset 1,000 times. The calibration of the model was estimated 8 
by comparing the predicted and observed survival probabilities at five years. For comparing 9 
the discrimination accuracy of two non-nested Cox models the U-statistic calculated by the 10 
Hmisc rcorrp.cens function was used. 11 
Detecting over-representation of genomic features 12 
Mutated cancer genes identified by the Cancer Genome Atlas Research Network (2015) [16] 13 
were examined at the sample level. The under-/over-representation of these features in 14 
samples assigned to a particular LPD signature was determined using the χ2 independence 15 
test. 16 
Pathway over-representation analysis and signature correlation analysis 17 
The GO biological process annotations were tested for over-representation (or under-18 
representation) in the lists of differentially expressed genes in each signature, using 19 
clusterProfiler version 3.4.4. For a given pathway and a given sample the pathway activation 20 
score was calculated as indicated in Levine et al. [24]. Using the complete combined dataset 21 
of all 8 datasets, Z-scores were calculated for each sample for each of the 17,697 MSigDB v6.0 22 
gene sets. These were correlated with DESNT γ values, and the top 20 sets with the highest 23 
absolute Pearson’s correlation were selected. The resulting p-values from pathway over-24 
representation analysis were adjusted for multiple testing using the false discovery rate. 25 
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 1 
Results 2 
Presence of DESNT signature as a continuous variable is associated with poor 3 
clinical outcome  4 
In our previous studies, LPD detected between three and eight underlying signatures (also 5 
called processes) in expression microarray datasets collected from prostate cancer samples 6 
after prostatectomy [14]. Decomposition of the MSKCC dataset [7] gave eight signatures 7 
[14].  Fig. 1a  illustrates the proportion of the DESNT expression signature identified in each 8 
MSKCC sample, with individual cancer samples being assigned as a “DESNT cancer” when 9 
the DESNT signature was the most abundant as shown in Fig. 1a and Fig. 1c. Based on PSA 10 
failure, patients with DESNT cancer always exhibited poorer outcome relative to other 11 
cancer samples  in the same dataset [14]. The implication is that it is the presence of regions 12 
of cancer containing the DESNT signature conferred poor outcome. If this idea is correct, we 13 
would predict that cancer samples containing a smaller contribution of DESNT signature, 14 
such as those shown in Fig. 1b for the MSKCC dataset, should also exhibit poorer outcome.  15 
To increase the power to test this prediction we combined transcriptome data from the 16 
MSKCC [7], CancerMap [14], Stephenson [15], and CamCap [6] studies (n=503). There was a 17 
significant association with PSA recurrence when the proportion of expression assigned to 18 
the DESNT signature was treated as a continuous variable (HR = 1.52, 95% CI=[1.36, 1.7], 19 
P = 9.0x10-14, Cox proportional hazard regression model). Outcome became worse as the 20 
proportion of DESNT signature increased. For illustrative purposes cancer samples were 21 
divided into four groups based on the proportion of DESNT, with 47.4% of cancer samples 22 
contained at least some DESNT cancer (proportion greater than 0.001; Fig. 2a). PSA failure 23 
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free survival at 60 months is 82.5%, 67.4%, 59.5% and 44.9% for the proportion of DESNT 1 
signature being <0.001, 0.001 to 0.3, 0.3 to 0.6, and >0.6, respectively (Fig. 2b). 2 
Nomogram for DESNT predicting PSA failure  3 
The proportion of DESNT cancer was combined with other clinical variables (Gleason grade, 4 
PSA levels, pathological stage, and the surgical margins status) in a Cox proportional 5 
hazards model and fitted to a combined dataset of 318 cancer samples (MSKCC , 6 
CancerMap , and Stephenson); CamCap cancer samples (n=185) were used for external 7 
validation. The proportion of DESNT was an independent predictor of worse clinical 8 
outcome (HR = 1.33, 95% CI=[1.14, 1.56], P = 3.0x10-4,) along with Gleason grade=4+3 9 
(HR = 2.43, 95% CI=[1.10, 5.37], P = 2.7x10-2), Gleason grade>7 (HR = 5.05, 95% CI=[2.35, 10 
10.89], P < 1x10-4), and positive surgical margins (HR = 1.65, 95% CI=[1.07, 2.56], P = 2.2x10-2) 11 
(Fig. S1: Supplementary Figure 1). PSA level and pathological stage were below the 12 
threshold of statistical significance (P = 0.09, HR = 1.14, 95% CI=[0.97, 1.34]) and (P = 0.055, 13 
HR = 1.51, 95% CI=[0.99, 2.31]) respectively. At internal validation, the Cox model obtained 14 
a 1,000 bootstrap-corrected C-index of 0.747, and at external validation a C-index of 0.795. 15 
Using this model, a nomogram was constructed for use of DESNT cancer information in 16 
conjunction with clinical variables to predict the risk of biochemical recurrence at one, three, 17 
five, and, seven years following prostatectomy (Fig. 2c, Fig. S1).  18 
LPD algorithm for detecting the presence of DESNT cancer in individual samples 19 
The ability of LPD to detect structure is likely to be dependent on sample size, cohort 20 
composition, disease severity range and data quality. We observed optimal decompositions 21 
varying between three and eight underlying signatures in different datasets [14]. When we 22 
examined the two datasets that had an optimal eight underlying signatures (MSKCC and 23 
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CancerMap) we noted a striking relationship: based on correlations of expression profiles; 1 
all eight of the LPD signatures appeared to be common (Fig. S2; R2 > 0.5). To provide a more 2 
consistent classification framework where the number of classes did not vary between 3 
datasets, we therefore used the MSKCC dataset and its decomposition into eight distinct 4 
signatures as a reference for identifying categories of prostate cancer type.  5 
LPD is a computer intensive procedure and analyses can take days to run on a high-6 
performance computing cluster. This would restrict ease of DESNT detection for clinical 7 
implementation. We therefore developed a variant of LPD called One Added Sample-LPD 8 
(OAS-LPD), where data from a single additional cancer sample could be decomposed into 9 
signatures, following normalisation, without repeating the entire LPD procedure. LPD 10 
model parameters [11] were first derived by decomposition of the MSKCC dataset into eight 11 
signatures. These signature parameters were then used as a framework for decomposition of 12 
additional data from single samples, selected in this case from a dataset, or in future from a 13 
patient undergoing assessment in the clinic. To test this procedure, we applied OAS-LPD 14 
individually to cancer samples from MSKCC, CancerMap, Stephenson, and CamCap (Fig. 15 
S3) and repeated Cox regression analysis and nomogram construction. Proportion of DESNT 16 
(P = 0.0011, HR = 1.53, 95% CI=[1.19, 1.98]), Gleason=4+3 (P = 0.0061, HR = 2.83, 95% 17 
CI=[1.35, 5.96]), Gleason>7 (P < 1x10-4, HR = 5.39, 95% CI=[2.54, 11.44]) and surgical margin 18 
status (P = 0.0015, HR = 2.00, 95% CI=[1.30, 3.07]) remained independent predictors of 19 
clinical outcome (Fig. S4). Notably the performance of the Cox model (internal validation C-20 
index=0.742; external validation C-index=0.786) was not significantly different to that of the 21 
original separate dataset Cox model (train dataset Z=-0.65, two-tailed P = 0.52; validation 22 
dataset Z = 0.89, two-tailed P = 0.38; U-statistic) and the nomogram (Fig. S5) had almost an 23 
identical presentation of parameters to that shown in Fig. 2c. This observation is consistent 24 
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the high degree of correlation between LPD and OAS-LPD DESNT gamma values across the 1 
MSKCC, CancerMap, Stephenson, and CamCap datasets P= 2.39x 10-110) 2 
New categories of prostate cancer 3 
We wished to determine whether LPD signatures were characterized by particular clinical or 4 
molecular features indicating that they represented distinct categories of prostate cancer. 5 
OAS-LPD using the MSKCC derived model of gene signatures was applied to all datasets 6 
(n=1958, Table 1) and each sample was assigned to the signature that was the most 7 
abundant. Samples from non-cancerous (benign) prostate tissue were more frequently 8 
assigned to LPD2, LPD4, and LPD8 than to the other groups (P < 0.05, χ2 test, Fig. S3, Table 9 
S1). When datasets with linked clinical data were combined (MSKCC, CancerMap, 10 
Stephenson, CamCap, Fig. 3a-c) primary cancers assigned to DESNT had worse outcome 11 
(P = 3.4x10-14, log-rank test, DESNT assigned samples vs the rest) while those assigned to 12 
LPD4 had improved outcome (P = 0.0081, log-rank test, LPD4 assigned samples vs the rest) 13 
as judged by PSA failure. Cancer samples with ERG-alterations assigned to signature LPD3 14 
also exhibited better outcome (P < 0.05; log-rank test, comparison to all other ETS positive 15 
cancer samples) in all three datasets where ERG status was available (Fig. 4b-d).  16 
To gain information about the new LPD categories we examined  the distribution of genetic 17 
alterations in the decomposition of the TGCA dataset [16] (Fig. 4a), LPD3 cancer samples 18 
had over-representation of ETS and PTEN gene alterations, and under-representation of 19 
CDH1 and SPOP gene alterations (P < 0.05, χ2 test, Table 2). LPD5 cancer samples exhibited 20 
exactly the reverse pattern of genetic alteration: there was under-repression of ETS and 21 
PTEN gene alterations and over-representation of SPOP and CHD1 alterations (Table 2). The 22 
statistically different distribution of ETS-gene alterations in samples assigned to LPD3, and 23 
13 
 
LPD5, observed in the TGCA dataset were confirmed in the CamCap and CancerMap 1 
dataset (Table 2). In summary we have identified three additional prostate cancer categories 2 
that have altered genetic and/or clinical associations: LPD3, LPD4, and LPD5 (Fig. 5) and 3 
that may be relevant for drug targeting.  4 
Altered patterns of gene expression and DNA methylation 5 
We examined samples assigned to each OAS-LPD signature for genes with significantly 6 
altered expression levels in all eight datasets (P < 0.05 after FDR correction, samples in LPD 7 
group vs all other LPD categories from the same dataset, Supplementary data 1). LPD3 8 
cancers samples exhibited seven commonly overexpressed genes including ERG, GHR, and 9 
HDAC1. Pathway analysis suggested the involvement of Stat3 gene signalling (Fig. S6a, 10 
Supplementary data 2). LPD5 exhibited 47 significantly overexpressed gene and 13 under-11 
expressed genes. Many of the genes had established roles in fatty acid metabolism and the 12 
control of secretion (Fig. S6b). LPD6-cancers and LPD8 cancers had failed to exhibit 13 
statistically significant changes in genetic alteration or clinical outcome in the current study 14 
but did have characteristic altered patterns of gene expression (Fig. S6c,e). The five genes 15 
commonly overexpressed in LPD6 cancers suggested involvement in metal ion homeostasis. 16 
30 genes were overexpressed and 36 genes under expressed in in LPD8 cancers including 17 
several genes involved in extracellular matrix organisation. Cross referencing differential 18 
methylation data available for the TCGA dataset with gene associated with each LPD group 19 
indicated that many expression changes may be explained, at least in part, by changes in 20 
DNA methylation (Fig. 5, Fig. S7, Supplementary data 3). 21 
DESNT as a signature of metastasis  22 
14 
 
The MSKCC study includes data from 19 metastatic cancer samples. For each metastatic 1 
sample, DESNT was the most abundant signature when OAS-LPD was applied (Fig. 3d). 2 
Two of the studied datasets (MSKCC and Erho) had publicly available annotations 3 
indicating that the patients from which primary cancer expression profiles were examined 4 
had progressed to develop metastasis after prostatectomy (Fig. S3). From nine cancer 5 
patients developing metastasis in the MSKCC dataset five occurred from samples in which 6 
the DESNT signature is most common (X2-test, P = 0.0017) and of 212 cancer patients 7 
developing metastases in the Erho dataset 50 were from DESNT cancers (X2-test, P = 0.0019) 8 
(Fig. S8). From these studies we concluded that DESNT cancers have an increased risk of 9 
developing metastasis, consistent with the higher risk of PSA failure. For the Erho dataset, 10 
membership of LPD1 was associated with lower risk of metastasis (X2-test, P = 0.026, Fig. 11 
S8).  12 
To further investigate the underlying nature of DESNT cancer we used the transcriptome 13 
profile for each primary prostate cancer sample to investigate associations with the 17,697 14 
signatures and pathways annotated in the MSigDB database. The top 20 signatures where 15 
expression was associated with proportion of DESNT are shown in Table S2. The third most 16 
significant correlation was to genes downregulated in metastatic prostate cancer. This 17 
resulting data gives additional clues to the underlying biology of DESNT cancer including 18 
associations with genes altered in ductal breast cancer, in stem cells and during FGFR1 19 
signaling.  20 
 21 
Discussion 22 
We have confirmed a key prediction of the DESNT cancer model by demonstrating that the 23 
presence of a small proportion of the DESNT cancer signature confers poorer outcome. The 24 
15 
 
proportion of DESNT signature can be considered a continuous variable such that as DESNT 1 
cancer content increases outcome became worse. This observation led to the development of 2 
nomograms for estimating PSA failure at three years, five years, and seven years following 3 
prostatectomy. The result provides an extension of previous studies in which nomograms 4 
incorporating Gleason score, Stage, and PSA value have been used to predict outcome 5 
following surgery [25]. 6 
 7 
The match between the eight underlying signatures detected for the MSKCC and 8 
CancerMap datasets was used as the basis for developing a novel classification framework 9 
for prostate cancer. A new algorithm called OAS-LPD was developed to allow rapid 10 
assessment of the presence of the signatures in individual cancer samples. In total four 11 
clinically and or genetically distinct subgroups were identified (DESNT, LPD3, LPD4, and 12 
LPD5, Fig. 5). The functional significance of the new disease groupings, for example in 13 
determining drug sensitivity, remains to be established. However, with the use of OAS-LPD 14 
it will be possible to undertake assessments of the response of patients in each of the groups 15 
DESNT, LPD3, LPD4, and LPD5 to drug treatments. There is limited overlap between the 16 
new classification and previously proposed subgroups based on genetic alterations [16,26–17 
29].  18 
Multiplatform data (expression, mutation, and methylation data from each cancer sample) 19 
are available for many cancer types, for example from The Cancer Genome Atlas. This has 20 
prompted the development of additional methods for sub-class discovery that can combine 21 
information from different platforms including the copula mixed model [30], Bayesian 22 
consensus clustering [31] and the iCluster model [16]. These approaches can suffer from the 23 
problem of sample assignment to a particular cluster or group, and the failure to take into 24 
16 
 
consideration the heterogeneous composition of individual cancer samples. These 1 
observations highlight the need to develop methods similar to LPD that can be applied to 2 
multiplatform data.  3 
 4 
An important issue for patients diagnosed with prostate cancer is that clinical outcome is 5 
highly variable and precise prediction of the course of disease progression at the time of 6 
diagnosis is not possible [32]. In some studies, the use of population PSA screening can 7 
reduce mortality from prostate cancer by up to 21% [33]. However many, if not most, 8 
prostate cancers that are currently detected by PSA screening are clinically insignificant [34]. 9 
Over-diagnosis of clinically insignificant prostate cancer is a major issue and is set to 10 
increase still further [35]. There is therefore an urgent need for the identification of cancer 11 
categories that are associated with clinically aggressive or indolent disease to allow the 12 
targeting of radical therapies to the men that need them. For breast cancer unsupervised 13 
hierarchical clustering of transcriptome data resulted in a classification system that is 14 
routinely used to guide the management and treatment of this disease. Here we established 15 
a novel classification framework for the analysis of prostate cancer that has its origins in 16 
unsupervised analyses of transcriptome data. In future studies we plan to analyse the utility 17 
of DESNT and other LPD processes (particularly LPD3, LPD4 and LPD5) in managing 18 
prostate cancer patients, including predicting response to drug treatment.  This will be 19 
performed through the assessment of LPD status in the contexts of established clinical trials. 20 
For evaluation we would plan to use each LPD assignment (eg DESNT, LPD3, LPD4 and 21 
LPD5) as a continuous variable as illustrated here by the development of a nomograms for 22 
the use of DESNT in predicting PSA failure. In conclusion our results highlight the 23 
17 
 
importance of devising and using more sophisticated approaches for the analysis of genomic 1 
datasets from all biological systems. 2 
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Legends 1 
Figure 1. LPD decomposition of the MSKCC dataset. (a) DESNT bar chart from the LPD 2 
decomposition of the MSKCC dataset [14].  showing the number ID assigned to 23 examples 3 
samples that had some amount of DESNT signature. (b,c) Pie charts showing the relative 4 
proportions of the eight LPD signatures in 23 example samples. DESNT is in red, other LPD 5 
signatures are represented by different colours as indicated in the key. The number next to 6 
each pie chart indicates which cancer it represents from the bar chart above. Individual 7 
cancer samples were assigned as a “DESNT cancer” when the DESNT signature was the 8 
most abundant; examples are shown in the right-hand box (c, ‘DESNT’). Many other cancer 9 
samples contained a smaller proportion of DESNT cancer and were associated with a poor 10 
outcome: examples shown in larger box (b, ‘SOME DESNT’).  11 
 12 
Figure 2. Stratification of prostate cancer samples based on the percentage of DESNT cancer 13 
present. For these analyses the data from the MSKCC, CancerMap, CamCap, and 14 
Stephenson datasets were combined (n=503). (a) Plot showing the proportion of DESNT 15 
signature in each cancer sample and the division into four groups of increasing DESNT. 16 
Group 1 samples have a proportion of less than 0.001 of the DESNT signature. (b) Kaplan-17 
Meier plot showing the Biochemical Recurrence (BCR) free survival based on proportion of 18 
DESNT cancer present as determined by LPD. Number of cancer patients in each Group are 19 
indicated (bottom right) and the number of PCR failures in each group are show in 20 
parentheses. The definition of Groups 1-4 is shown in Fig. 2a. Cancer samples with 21 
proportions up to 0.3 DESNT (Group 2) exhibited poorer clinical outcome (X2-test, P = 0.011) 22 
compared to cancer samples lacking DESNT (<0.001). Cancer samples with the 23 
intermediate (0.3 to 0.6) and high (>0.6) proportions of DESNT also exhibited significantly 24 
worse outcome (respectively P = 2.6 × 10-5 and P = 8.3 × 10-9 compare to cancer samples 25 
24 
 
lacking DESNT. The combined log-rank P = 1.3x10-8). (c) Nomogram model developed to 1 
predict PSA free survival at one, three, five, and seven years using proportion of DESNT. 2 
Assessing a single patient each clinical variable has a corresponding point score (top scales). 3 
The point scores for each variable are added to produce a total points score for each patient. 4 
The predicted probability of PSA free survival at one, three, five, and seven years can be 5 
determined by drawing a vertical line from the total points score to the probability scales 6 
below. 7 
 8 
Figure 3. Prediction of clinical outcome according to OAS-LPD group. (a-c) Kaplan-Meier 9 
plots showing PSA free survival outcomes for the cancer patients assigned to LPD groups in 10 
analyses of the combine MSKCC, CancerMap, CamCap, and Stephenson datasets: (a) 11 
comparison of all LPD groups (LPD7 is DESNT); (b) cancer patients assigned to LPD4 12 
compared to patients assigned to all other LPD groups; (c) cancer patients assigned to 13 
DESNT (LPD7) compared to cancers assigned to all other LPD groups. (d) OAS-LPD 14 
signature assignment proportions for the 19 metastatic tissue samples reported as part of the 15 
MSKCC dataset. In all cases DESNT (LPD7) was the dominant expression signature 16 
detected. 17 
 18 
Figure 4. (a) OAS-LPD sub-groups in The Cancer Genome Atlas Dataset (n=333). Cancer 19 
samples were assigned to subgroups based on the most prominent signature as detected by 20 
OAS-LPD. The types of genetic alteration are shown for each gene (mutations, fusions, 21 
deletions, and over-expression). Clinical parameters including biochemical recurrence (BCR) 22 
are represented at the bottom together with groups for iCluster, methylation, somatic copy 23 
number alteration (SVNA), and messenger RNA (mRNA)[16]. Comparison of the frequency 24 
of genetic alterations present in each subgroup are shown in Table 2. (b-d) Kaplan-Meier 25 
25 
 
plots showing PSA free survival outcomes for ETS-rearrangement positive cancers in LPD3 1 
compared to all other ETS-positive cancers for the CancerMap, CamCap, and TCGA 2 
datasets. 3 
 4 
Figure 5. A classification framework for prostate cancer. Based on the analyses of genetic 5 
and clinical correlations we consider that there is good evidence for the existence of LPD3, 6 
LPD4, and LPD5 as separate cancer categories, moderate evidence of the existence of LPD6 7 
and LPD8 (based on alteration of expression only), and weak evidence for LPD1. The 8 
methylation column list all genes that exhibit differential expression and that also contain at 9 
least one locus that is differentially methylated. 10 
 11 
 12 
Table 1 
 
Dataset Primary Normal Type Platform Citation 
MSKCC [7] 131 29 FF Affymetrix Exon 1.0 ST v2 Taylor et al. 2010  
CancerMap [14] 137 17 FF Affymetrix Exon 1.0 ST v2 Luca et al. 2017  
Stephenson [15] 78 11 FF Affymetrix U133A Stephenson et al. 2005 
Klein [17] 182 0 FFPE Affymetrix Exon 1.0 ST v2 Klein et al. 2015 
CamCap [6] 147 73 FF Illumina HT12 v4.0 BeadChip Ross-Adams et al. 2015 
TCGA [16] 333 43 FF Illumina HiSeq 2000 RNA-Seq v2 TCGA network 2015 
Erho [18] 545 0 FFPE Affymetrix Exon 1.0 ST v2 Erho et al. 2013 
Karnes [19] 232 0 FFPE Affymetrix Exon 1.0 ST v2 Karnes et al. 2013 
Table 1. Transcriptome datasets. The MSKCC study additionally reported expression 
profiles from 19 metastatic cancers. The ethical approvals obtained for each dataset are listed 
in the original publications.   
 
Table 2 
 
 TCGA CancerMap CamCap 
ETS- ETS+ χ2 P-val ERG- ERG+ χ2 P-val ERG- ERG+ χ2 P-val 
LPD1 8 3 0.0588 13 4 0.0851 0 3 0.235 
LPD2 4 8 0.827 3 3 1 0 2 0.467 
LPD3 9 67 1.45x10-08 5 15 0.00977 4 17 0.00299 
LPD4 14 21 1 14 15 0.619 1 2 0.987 
LPD5 65 5 2.20x10-16 19 1 0.000180 34 0 1.15x10-11 
LPD6 13 22 0.802 5 5 1 2 4 0.657 
DESNT 13 66 1.17x10-06 6 15 0.0207 9 24 0.00274 
LPD8 9 6 0.193 8 4 0.540 4 1 0.371 
          
 PTEN SPOP CHD1 
 Non-homdel Homdel χ2 P-val 
Non-
mut Mut χ2 P-val Non-homdel Homdel χ2 P-val 
LPD1 10 1 0.896 8 3 0.213 9 2 0.309 
LPD2 12 0 0.284 12 0 0.436 12 0 0.756 
LPD3 55 21 0.000894 73 3 0.0400 76 0 0.0211 
LPD4 35 0 0.0174 31 4 1 34 1 0.603 
LPD5 67 3 0.00830 51 19 4.46x10-06 57 13 7.69x10-06 
LPD6 29 6 0.903 32 3 0.825 34 1 0.603 
DESNT 60 19 0.0167 75 4 0.0795 76 3 0.432 
LPD8 15 0 0.195 14 1 0.889 14 1 1 
Table 2. Correlation of OAS-LPD subgroups with genetic alterations in The Cancer Genome 
Atlas Dataset. Statistically significant differences are highlighted in grey.  
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